MCF Advisors’s TherapeuticsMD TXMD Stock Holding History

MCF Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-8,135	Closed	-$508K	–	503
2020 Q2	$508K	Buy	+8,135	New	+$474K	0.07%	71

Other funds holding TXMD

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

MCF Advisors's TXMD Position: Q3 2020 in Review

MCF Advisors sold out of TherapeuticsMD (TXMD) in Q3 2020, closing a stake of 8,135 shares — an estimated $508K sold.

MCF Advisors first reported a position in TXMD in Q2 2020 and held it in 1 quarter. The position peaked at $508K in Q2 2020. 142 funds tracked by Wall St. Rank hold TXMD as of Q3 2020.

MCF Advisors reported no remaining TherapeuticsMD position as of Q3 2020 after selling out during the quarter.
MCF Advisors sold 8,135 TherapeuticsMD shares in Q3 2020, an estimated $508K.
MCF Advisors first reported a position in TherapeuticsMD in Q2 2020 and held it in 1 quarter.
MCF Advisors's TherapeuticsMD position peaked at $508K in Q2 2020.
142 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2020.

Based on MCF Advisors's 13F filing for Q3 2020, filed 12 Nov 2020.